EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 27 / No 3 (Mars 2011) Med Sci (Paris), 27 3 (2011) 285-288 References
Free Access
Issue
Med Sci (Paris)
Volume 27, Number 3, Mars 2011
Page(s) 285 - 288
Section M/S revues
DOI https://doi.org/10.1051/medsci/2011273285
Published online 30 March 2011
  1. LazennecG, JorgensenC. Concise review: adult multipotent stromal cells and cancer: risk or benefit?. Stem Cells 2008 ; 26 : 1387-1394. [CrossRef] [PubMed] [Google Scholar]
  2. WangH, CaoF, DeA, et al. Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 2009 ; 27 : 1548-1558. [CrossRef] [PubMed] [Google Scholar]
  3. LoebingerMR, KyrtatosPG, TurmaineM, et al. Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 2009 ; 69 : 8862-8867. [CrossRef] [PubMed] [Google Scholar]
  4. HoIA, ChanKY, NgWH, et al. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 2009 ; 27 : 1366-1375. [CrossRef] [PubMed] [Google Scholar]
  5. GutovaM, NajbauerJ, FrankRT, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008 ; 26 : 1406-1413. [CrossRef] [PubMed] [Google Scholar]
  6. DwyerRM, Potter-BeirneSM, HarringtonKA, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007 ; 13 : 5020-5027. [CrossRef] [PubMed] [Google Scholar]
  7. KimDS, KimJH, LeeJK, et al. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev 2009 ; 18 : 511-519. [CrossRef] [PubMed] [Google Scholar]
  8. BirnbaumT, RoiderJ, SchankinCJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. Neurooncol 2007 ; 83 : 241-247. [CrossRef] [Google Scholar]
  9. FengB, ChenL.. Review of mesenchymal stem cells and tumors: executioner or coconspirator?. Cancer Biother Radiopharm 2009 ; 24 : 717-721. [CrossRef] [PubMed] [Google Scholar]
  10. SpaethE, KloppA, DembinskiJ, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008 ; 15 : 730-738. [CrossRef] [PubMed] [Google Scholar]
  11. KiddS, SpaethE, DembinskiJL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009 ; 27 : 2614-2623. [CrossRef] [PubMed] [Google Scholar]
  12. KarnoubAE, DashAB, VoAP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007 ; 449 : 557-563. [CrossRef] [PubMed] [Google Scholar]
  13. MakinoshimaH, DezawaM.. Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway. FEBS Lett 2009 ; 583 : 3697-3703. [CrossRef] [PubMed] [Google Scholar]
  14. CoffeltSB, MariniFC, WatsonK, et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA 2009 ; 106 : 3806-3811. [CrossRef] [Google Scholar]
  15. SpaethEL, DembinskiJL, SasserAK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009 ; 4 : e4992. [CrossRef] [PubMed] [Google Scholar]
  16. SasserAK, SullivanNJ, StudebakerAW, et al. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. Faseb J 2007 ; 21 : 3763-3770. [CrossRef] [PubMed] [Google Scholar]
  17. MolloyAP, MartinFT, DwyerRM, et al. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 2009 ; 124 : 326-332. [CrossRef] [PubMed] [Google Scholar]
  18. DjouadF, PlenceP, BonyC, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003 ; 102 : 3837-3844. [CrossRef] [PubMed] [Google Scholar]
  19. ZhuY, SunZ, HanQ, et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009 ; 23 : 925-933. [CrossRef] [PubMed] [Google Scholar]
  20. MartinFT, DwyerRM, KellyJ, et al. Potential role of mesenchymal stem cells (CSMs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010 ; 124 : 317-326. [CrossRef] [PubMed] [Google Scholar]
  21. OrimoA, GuptaPB, SgroiDC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005 ; 121 : 335-348. [CrossRef] [PubMed] [Google Scholar]
  22. MishraPJ, MishraPJ, HumeniukR, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008 ; 68 : 4331-4339. [CrossRef] [PubMed] [Google Scholar]
  23. VilaltaM, DeganoIR, BagoJ, et al. Human adipose tissue-derived mesenchymal stromal cells as vehicles for tumor bystander effect: a model based on bioluminescence imaging. Gene Ther 2009 ; 16 : 547-557. [CrossRef] [PubMed] [Google Scholar]
  24. KucerovaL, AltanerovaV, MatuskovaM, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007 ; 67 : 6304-6313. [CrossRef] [PubMed] [Google Scholar]
  25. LoebingerMR, EddaoudiA, DaviesD, JanesSM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009 ; 69 : 4134-4142. [CrossRef] [PubMed] [Google Scholar]
  26. FritzV, NoelD, BouquetC, et al. Antitumoral activity and osteogenic potential of hATF-expressing mesenchymal stem cells in a murine model of osteolytic tumor. Stem Cells 2008 ; 26 : 2981-2990. [CrossRef] [PubMed] [Google Scholar]
  27. ChenXC, WangR, ZhaoX, et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered CSMs. Carcinogenesis 2006 ; 27 : 2434-2441. [CrossRef] [PubMed] [Google Scholar]
  28. LiX, LuY, HuangW, et al. In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol Oncol 2006 ; 24 : 151-158. [CrossRef] [PubMed] [Google Scholar]
  29. KomarovaS, KawakamiY, Stoff-KhaliliMA, et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006 ; 5 : 755-766. [CrossRef] [PubMed] [Google Scholar]
  30. WalkleyCR, OlsenGH, DworkinS, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007 ; 129 : 1097-1110. [CrossRef] [PubMed] [Google Scholar]
  31. RaaijmakersMH, MukherjeeS, GuoS, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010 ; 464 : 852-857. [CrossRef] [PubMed] [Google Scholar]
  32. MenendezP, CatalinaP, RodriguezR, et al. Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. Exp Med 2009 ; 206 : 3131-3141. [CrossRef] [Google Scholar]
  33. RogerM, ClavreulA, MeneiP. Cellules stromales mésenchymateuses : vecteurs cellulaires de nanoparticules au sein de tumeurs cérébrales. Med Sci (Paris) 2011 ; 27 : 234-236. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.